Topics

Samsung Bioepis’ Etanercept Nod Prompts US Lawsuit

01:24 EDT 2 May 2019 | SCRIP

The FDA has approved Samsung Bioepis’ Eticovo as the second biosimilar competitor to Amgen’s blockbuster rheumatoid arthritis biologic Enbrel. Amgen...

      

Related Stories

 

Original Article: Samsung Bioepis’ Etanercept Nod Prompts US Lawsuit

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis’ Etanercept Nod Prompts US Lawsuit"

Quick Search

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...